Ocular Therapeutix (OCUL) Research & Development (2013 - 2026)
Ocular Therapeutix (OCUL) posted quarterly Research & Development of $54.1 million for Q2 2026, up 5.98% year-over-year from $51.1 million in Q2 2025, and down 18.24% on a QoQ basis from $66.2 million in Q1 2026.
Ocular Therapeutix (OCUL) Research & Development (2013 - 2026) Analysis & Trends
Ocular Therapeutix has reported Research & Development for 14 years, with the latest figure at $54.1 million in Q2 2026.
- Research & Development for Q2 2026 came in at $54.1 million, up 5.98% year-over-year; the trailing twelve-month figure through Jun 2026 was $223.5 million (up 29.96% YoY), and the FY2025 annual result was $197.1 million, up 54.42% from the prior year.
- Research & Development fell to $54.1 million in Q2 2026, from $66.2 million in the prior quarter.
- Over five years, Research & Development peaked at $66.2 million in Q1 2026 and troughed at $13.1 million in Q1 2022.
- A 5-year average of $31.1 million and a median of $24.8 million in 2024 frame the typical range for Research & Development.
- The widest annual swing landed in 2022, when Research & Development decreased 5.48%; it then jumped 153.1% in 2024.
- A 5-year view of Research & Development shows it stood at $13.5 million in 2022, then rose by 19.58% to $16.2 million in 2023, then jumped by 153.1% to $41.0 million in 2024, then grew by 23.94% to $50.8 million in 2025, then rose by 6.57% to $54.1 million in 2026.
- Per Business Quant data, the three most recent Research & Development figures were $54.1 million in Q2 2026, $66.2 million in Q1 2026, and $50.8 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.37 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 394.92 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 612.28 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1,146.05 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 97.90 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 413.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 210.03 Mn |
| 10 | Ocular Therapeutix | 2.20 Bn | 2.20 Bn | 11.46 Mn | 54.14 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 54.14 Mn |
| Mar 31, 2026 | 66.21 Mn |
| Dec 31, 2025 | 156.13 Mn |
| Sep 30, 2025 | 13.09 Mn |
| Jun 30, 2025 | 51.08 Mn |
| Mar 31, 2025 | 14.15 Mn |
| Dec 31, 2024 | 96.89 Mn |
| Sep 30, 2024 | 37.05 Mn |
| Jun 30, 2024 | 28.86 Mn |
| Mar 31, 2024 | 10.18 Mn |
| Dec 31, 2023 | 9.25 Mn |
| Sep 30, 2023 | 15.02 Mn |
| Jun 30, 2023 | 15.09 Mn |
| Mar 31, 2023 | 14.75 Mn |
| Dec 31, 2022 | 3,000.00 |
| Sep 30, 2022 | 10.19 Mn |
| Jun 30, 2022 | 13.10 Mn |
| Mar 31, 2022 | 9.06 Mn |
| Dec 31, 2021 | 9.14 Mn |
| Sep 30, 2021 | 12.72 Mn |